Abirakast 250 mg Tablet

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Abirakast 250 mg Tablet contains abiraterone acetate, an androgen biosynthesis (CYP17) inhibitor. Its labelling describes it for the treatment of prostate gland cancer, and it may be prescribed for other conditions or in combination with other medicines such as chemotherapy as the doctor sees fit. It is described as preventing male hormone production by stopping the specific enzyme responsible for androgen production, which slows the growth of prostate cancer.

Active ingredient
Abiraterone acetate
Strength
250 mg
Dosage form
Oral tablet
Therapeutic class
Androgen biosynthesis inhibitor (CYP17 inhibitor)
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Described for the treatment of prostate cancer
  • Also listed for sickle cell anaemia, blood cancer (acute lymphocytic leukemia), soft tissue sarcoma, and Hodgkin’s disease
  • Described as stopping the enzyme responsible for androgen production, slowing the growth of prostate cancer
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Swallowed whole; the tablet should not be broken, chewed, or crushed
  • Taken on an empty stomach, following the doctor’s instructions
  • The doctor may pair it with other medicines, such as chemotherapy, as needed

Described Side Effects

Commonly described side effects include:

  • Edema (swelling) and joint swelling
  • Vomiting
  • Decreased potassium level in the blood
  • Fatigue
  • Anaemia
  • Diarrhoea
  • High blood pressure
  • Cough

These are described as commonly temporary. The doctor should be consulted if they are bothersome.

Precautions

  • The doctor should be informed about pregnancy or breastfeeding, as it is not suitable at those times, and about liver, kidney, blood pressure, or heart issues
  • The doctor may request checks of liver function, blood pressure, and blood potassium level, which should be cooperated with
  • Everyone should use effective contraception to avoid pregnancy

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical and healthcare products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling it contains abiraterone acetate and is used for the treatment of prostate gland cancer, and for other conditions as the doctor sees fit. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.

Its labelling describes it as swallowed whole on an empty stomach, without breaking, chewing, or crushing, following the doctor’s instructions.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services